Johnson DE - Search Results

1

Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides.

Shangary S, Oliver CL, Tillman TS, Cascio M, Johnson DE. Shangary S, et al. Among authors: johnson de. Mol Cancer Ther. 2004 Nov;3(11):1343-54. Mol Cancer Ther. 2004. PMID: 15542773

2

Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death.

Shangary S, Johnson DE. Shangary S, et al. Among authors: johnson de. Biochemistry. 2002 Jul 30;41(30):9485-95. doi: 10.1021/bi025605h. Biochemistry. 2002. PMID: 12135371

3

(-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance.

Oliver CL, Miranda MB, Shangary S, Land S, Wang S, Johnson DE. Oliver CL, et al. Among authors: johnson de. Mol Cancer Ther. 2005 Jan;4(1):23-31. Mol Cancer Ther. 2005. PMID: 15657350

4

Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death.

Emert-Sedlak L, Shangary S, Rabinovitz A, Miranda MB, Delach SM, Johnson DE. Emert-Sedlak L, et al. Among authors: johnson de. Mol Cancer Ther. 2005 May;4(5):733-42. doi: 10.1158/1535-7163.MCT-04-0301. Mol Cancer Ther. 2005. PMID: 15897237

5

Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells.

Li R, Boehm AL, Miranda MB, Shangary S, Grandis JR, Johnson DE. Li R, et al. Among authors: johnson de. Neoplasia. 2007 Oct;9(10):801-11. doi: 10.1593/neo.07394. Neoplasia. 2007. PMID: 17971900 Free PMC article.

6

Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family.

Shangary S, Johnson DE. Shangary S, et al. Among authors: johnson de. Leukemia. 2003 Aug;17(8):1470-81. doi: 10.1038/sj.leu.2403029. Leukemia. 2003. PMID: 12886234 Review.

7

Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.

Li C, Li R, Grandis JR, Johnson DE. Li C, et al. Among authors: johnson de. Mol Cancer Ther. 2008 Jun;7(6):1647-55. doi: 10.1158/1535-7163.MCT-07-2444. Mol Cancer Ther. 2008. PMID: 18566236 Free PMC article.

8

Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.

Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE. Li C, et al. Among authors: johnson de. Mol Cancer Ther. 2009 Aug;8(8):2211-20. doi: 10.1158/1535-7163.MCT-09-0327. Epub 2009 Jul 28. Mol Cancer Ther. 2009. PMID: 19638453 Free PMC article.

9

ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.

Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. Li R, et al. Among authors: johnson de. Mol Pharmacol. 2009 May;75(5):1231-9. doi: 10.1124/mol.108.052969. Epub 2009 Feb 25. Mol Pharmacol. 2009. PMID: 19246337 Free PMC article.

10

Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation.

Miranda MB, Redner RL, Johnson DE. Miranda MB, et al. Among authors: johnson de. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3081-90. doi: 10.1158/1535-7163.MCT-07-0514. Epub 2007 Dec 7. Mol Cancer Ther. 2007. PMID: 18065491

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,451 results

Search Page

Filters